The T Cell Response to Staphylococcus aureus.

Staphylococcus aureus (S. aureus) is a dangerous pathogen and a leading cause of both nosocomial and community acquired bacterial infection worldwide. However, on the other hand, we are all exposed to this bacterium, often within the first hours of life, and usually manage to establish equilibrium and coexist with it. What does the adaptive immune system contribute toward lifelong control of S. aureus? Will it become possible to raise or enhance protective immune memory by vaccination? While in the past the S. aureus-specific antibody response has dominated this discussion, the research community is now coming to appreciate the role that the cellular arm of adaptive immunity, the T cells, plays. There are numerous T cell subsets, each with differing functions, which together have the ability to orchestrate the immune response to S. aureus and hence to tip the balance between protection and pathology. This review summarizes the state of the art in this dynamic field of research.

1. Introduction

For almost 30 years, the relationship between Staphylococcus aureus (S. aureus) and T cells has intrigued microbiologists and immunologists alike. In 1987, only three years after the molecular characterization of the T cell receptor, the mode of action of the staphylococcal enterotoxins was elucidated by Bernhard Fleischer and Hubert Schrezenmeier [1]. They showed that these bacterial toxins—the so-called superantigens—are extremely potent T cell activators. To date, 23 superantigen genes have been described in S. aureus [2]. While it can only be speculated what advantage S. aureus may gain from excessive T cell activation, two conclusions may be drawn: first, T cells must be important in this pathogen-host interaction; and, second, the T cell reaction to S. aureus bears pathogenic potential.

S. aureus is a notorious pathogen causing a broad range of infections both in and outside hospitals [3,4]. However, persistent colonization of nose and skin is around 1000 times more common than are infections necessitating treatment [5,6,7,8]. Most individuals are continually exposed to S. aureus from the first hours after birth and yet manage to establish and maintain equilibrium with the micro-organism for a lifetime [9]. How is this achieved? When does it fail? In the following, our current knowledge of the roles of T cells both in protection and in S. aureus-related immune pathology will be discussed. General properties of T cells as well as of innate lymphoid cells (ILCs), their “older siblings”, will be reviewed in the Appendix.

The facultative pathogen S. aureus commands an impressive armory of virulence factors, many of which challenge the immune system [10,11,12]. Defense against this “superbug” relies first and foremost on the innate immune system in which professional phagocytes, mainly neutrophils, act in concert with the complement system [13,14,15]. The adaptive immune system, comprising T cells, B cells and antibodies, can facilitate, focus and enhance innate immunity [16].

How can T cells contribute to antibacterial immunity? Extracellular S. aureus, bacteria are engulfed and destroyed by phagocytes and this process is greatly facilitated by the binding of specific antibodies to the microbial surface. Such antibodies opsonize S. aureus for phagocytosis via complement activation and immunoglobulin-Fc receptors on phagocytes [15]. In this process of opsonophagocytosis, T lymphocytes have a dual function: On the one hand, they are important for the generation of opsonizing antibodies, because T cell help is required for antibody affinity maturation as well as for class switch [17]. On the other hand, T cells promote phagocytosis by recruiting neutrophils and macrophages from the bone marrow to the site of infection [18]. However, S. aureus is not exclusively an extracellular bacterium but can also adapt to the intracellular milieu, which enables it to persist and even divide inside host cells [19]. As long as the bacteria reside inside macrophage phagosomes their elimination is promoted by T cell cytokines, most prominently by IFN-γ [18]. However, once the bacteria escape from the phagosome into the cytoplasm, they are beyond the reach of T helper cells (TH). The infected cell must now be lysed by cytotoxic T cells (CTLs) or by natural killer cells (NK) [20] so as to release the bacteria and make them accessible to a new round of phagocytosis and killing. Finally, T cells are essential for (re)establishing immune homeostasis by dampening inflammatory processes. Regulatory T cells (Tregs) are specialized in this vital immune function [18]. Figure 1 shows a model of the potential roles of T cells in the anti-S. aureus defense network.

Figure 1

Model of the multifaceted role of T cells in anti-staphylococcal immune defense. The immune defense against Staphylococcus aureus crucially depends on the bactericidal activity of phagocytes, especially neutrophils and macrophages. Uptake and bacterial killing is greatly facilitated by opsonization of the bacteria by complement and/or antibodies. T cells can contribute to this process of opsonophagocytosis by: (1) providing help for B cells; (2) promoting the bactericidal potential of macrophages; and (3) recruiting phagocytes from the bone marrow to the site of infection. Once S. aureus has invaded host cells to persist in intracellular niches, cytotoxic T cells would be required to kill the infected cell, releasing S. aureus for a second round of opsonophagocytosis. Tregs have a vital function in dampening inflammatory processes and restoring homeostasis after resolution of the infection. CTL: Cytotoxic T lymphocyte; TFH: T follicular helper cell; TH: T helper cell; Treg: regulatory T cell.

2. The role of T Cells in S. aureus Control

There is now general agreement that T cells are important for protection from S. aureus infection [21,22]. This is based on observations in humans, livestock and experimental animals. Many groups have contributed evidence for the importance of T cell-derived IL-17 as well as IFN-γ.

2.1. Evidence from Mouse Models

In experimental mouse models multiple factors influence the susceptibility to S. aureus infection, the decisive T effector cell type as well as the protective cytokines: (1) the mouse strain; (2) the S. aureus strain; and (3) the type and duration of the infection. BALB/c mice, for example, rapidly succumb to blood stream infection with S. aureus, while C57BL6 mice are more resistant [23]. The opposite is true in skin and soft tissue infection [24,25]. The multifaceted role of T cells in the interplay between pathogen and host may be illustrated by a model of systemic S. aureus infection in C57BL6 mice, where it differed between the acute and chronic disease phase. In early disease, animals deficient in T cells, B cells and NK cells had no apparent defect in S. aureus clearance; T cells appeared to be dispensable [23]. However, during chronic infection—mice were monitored for 60 days—T cells made an important contribution to S. aureus control, even though the animals were not able to clear the infection completely [26]. Remarkably, while the T cells proliferated vigorously when exposed to the bacteria ex vivo during acute infection, this response was completely abolished in the chronic phase. Not only was the specific anti-S. aureus T cell response affected, but T cell reactivity generally was blunted [26]. The profound T cell suppression in chronic S. aureus infection was attributed to myeloid-derived suppressor cells (MDSCs) with a minor contribution from Tregs [27].

Following experimental colonization, C57BL6 mice spontaneously cleared S. aureus from the nose within 14 d. This was dependent on T cells, IL-17 and neutrophil influx but not on antibody production or IL-23 [28].

In skin and soft tissue infection, IL-17 had a crucial role in bacterial clearance, limiting lesion size. Cytokines of the IL-17 family may be generated by different cell types [29,30,31,32]. In a seminal study the group of Ishigame identified CD4+ TH17 cells as the main producers of IL-17A, whereas IL-17F was released by a broader range of cells [33]. Cho and coworkers reported γδ T cells to be the main producers of IL-17 in skin and soft tissue infection [34]. Similarly, in a murine model of wound infection, γδ T cells infiltrated the site of infection within three days, and many of them secreted IL-17, which reduced the local bacterial load [35]. In line with this, genetic deficiency in γδ T cells increased the bacterial burden in skin infection [36]. With repeated cutaneous infection the S. aureus-induced lesions became smaller in BALB/c but not in C57BL6 mice. Both TH17 cells and antibodies were induced and each provided some degree of protection upon adoptive transfer [25].

Similarly, in peritonitis, IL-17 producing γδ T cells acquired memory behavior, reacting more rapidly upon S. aureus re-challenge [37].

For survival of blood stream infection, in contrast, IFN-γ-competent CD4+ T cells were essential [38]. In accordance with this, the time course of disease did not differ between WT and IL-17-KO mice in a lethal intravenous (i.v.) infection model (C57BL6) [39]. When mice with severe combined immune deficiency (SCID), who are genetically deficient of adaptive immune cells, were reconstituted with human immune cells, the activation of the γδ T cell pool greatly improved the control of systemic S. aureus infection. This was correlated with the production of human IFN-γ. IL-17 measurements were not reported in this early study [40].

S. aureus pneumonia, is special in that the inflammatory mechanisms of anti-bacterial defense easily cause life threatening organ damage by interfering with gas exchange in the lungs. This may explain the ambiguous role of T cells documented in murine pneumonia models (all using C57BL6 mice). Following infection, S. aureus quickly activated conventional T lymphocytes in the lungs as well as in the draining lymph nodes, and this could be attributed partly to superantigen action [41]. Another group observed rapid accumulation of γδ T cells in the lungs, and γδ T cell-deficient animals showed delayed IL-17 production, neutrophil influx and bacterial clearance, implying a protective role for this T cell subset in S. aureus pneumonia. On the flip side of the coin, tissue damage was more severe in γδ T cell-competent animals, and these animals were sicker. Nevertheless, in this model survival was similar both in γδ T cell competent and in deficient animals [42]. Another study documented important roles for IL-17 and IL-22 in protection from S. aureus pneumonia. IL-17 was produced by both CD4+ TH17 cells and γδ T cells. Co-infection with influenza increased bacterial burden and death. This was correlated with impairment of the IL-17 (and IL-22) response, while rescuing the IL-17-production by IL-23 application led to increased survival of the animals [43]. While this makes the case for a protective role of T cells in S. aureus pneumonia, the group of Parker reported a detrimental role of T cells since all CD4+ T cell-deficient mice survived, whereas all T cell competent animals died. The improved survival of the T cell-depleted animals was associated with reduced inflammation, e.g., abolishment of IL-17 release into the bronchoalveolar lavage fluid. Despite the dampened inflammation, bacterial clearance was more efficient in T cell-deficient animals [41].

Vaccination Studies in Mice

Does the encounter with S. aureus or its components induce immune memory, and if so, does this confer clinical protection? Two strategies have been followed to answer this question: First, immunization with S. aureus components or whole inactivated S. aureus cells, and second, immunization with live S. aureus. The latter can be considered both as a vaccine approach and as a model of recurrent infection. Numerous vaccine studies in mice have shown clinical protection, which, while usually not sterilizing, clearly mitigated the disease course and reduced the bacterial load during challenge infection [44]. T cells have been shown to be essential for vaccine protection; depending on the model used either IL-17 or IFN-γ was the crucial protective cytokine.

In S. aureus bloodstream infection, immunization with ClfA in alum reduced the bacterial burden and improved survival. Interleukin-17 was required for protection. In contrast, anti-ClfA antibodies, which were induced in abundance, did not confer protection upon transfer to naïve animals [39]. IL-17-producing T lymphocytes were also essential for protection against S. aureus blood stream infection following vaccination with Als3p (in alum), an antigen derived from Candida albicans conferring cross-protection against S. aureus [38]. Similar results were obtained with the S. aureus iron scavenger IsdB as a vaccine antigen. In this case, specific antibodies, which were elicited by the vaccine in large amounts, were also protective but only in T cell-competent animals. The effect of passive vaccination with a monoclonal antibody targeting IsdB depended on the presence of CD4+ T cells as well [45]. Passive vaccination by surface-binding antibodies such as the anti-IsdB monoclonal antibodies is assumed to act by opsonizing S. aureus for phagocytosis. In this setting, the crucial role of IL-17-producing T cells can be explained by the fact that phagocyte recruitment and activation is strongly amplified by the action of this cytokine. While the protective action of antibodies depended on functional T cells, the opposite was not true: Even in the absence of neutralizing antibodies, protection from systemic S. aureus infection has been achieved after nasal vaccination with S. aureus ClfA coated on nanoparticles [46]. Moreover, in combination with a TH1 polarizing adjuvant the vaccine antigen ClfA conferred clinical protection in an S. aureus peritonitis model [47]. Finally, a peptide construct mimicking S. aureus peptidoglycan—followed by a boost with inactivated S. aureus cells—provided partial protection from an i.v. challenge infection. This was associated with increased numbers of TH1 and TH17 cells in the spleen [48].

Repeated S. aureus infection—or vaccination with live bacteria—conferred clinical protection as well. In skin and soft tissue infection, both TH17 cells and antibodies contributed to the observed reduction of lesion size in S. aureus-experienced animals [25]. The S. aureus bacterial load was also significantly reduced when a high dose challenge infection was preceded by repeated peritoneal infection with a low bacterial dose. In this case protection was associated with strongly increased production of IFN-γ by peritoneal CD4+ and CD8+ T cells. Remarkably, in vitro-expanded S. aureus-specific TH1 but not TH17 cells from S. aureus-primed animals transferred clinical protection to naïve mice. The bacterial burden in the recipient animals was reduced about 100-fold, a remarkably large effect [47]. Interestingly, in the same infection model, IL-17-producing γδ T cells were more effective at the initial stage of infection [49]. Hence disease kinetics adds a further layer of complexity to the effects of T cells in S. aureus-host interaction.

2.2. Evidence from Livestock

In livestock, especially in cattle, S. aureus is one of the leading infective agents in acute and chronic mastitis causing substantial economic losses worldwide [50,51,52]. Estimated costs range from US$ 38–130 per dairy cow and year [52,53]. The decrease in milk production and the need to dispose of the milk of infected animals are the main cost factors [54]. Therefore, most of the few studies addressing the interplay between S. aureus and T cells in livestock are focused on bovine mastitis.

In comparison with healthy cows, animals suffering from staphylococcal mastitis had significantly elevated numbers of γδ T cells in the blood, whereas both αβ T cells and γδ T cells were increased in the milk [55]. The increase of αβ T cells in the milk was mainly due to CD4+ T cells, and several groups reported increased CD4+:CD8+ ratios in cattle with mastitis [55,56,57]. However, there are also contrasting reports of lowered CD4+:CD8+ ratios in S. aureus mastitis [58,59,60]. Cows having substantially more CD4+ T cells than CD8+ T cells in their mammary gland secretions appear to be more mastitis-resistant suggesting that CD4+ T cells are protective [58]. The role of γδ T cells, which appear to be preferentially recruited to the mammary gland during infection, remains to be elucidated [55].

Vaccination Studies in Cattle

Vaccination could be a promising way to prevent intramammary infections. Many vaccine types have been developed, some are commercially available (reviewed in [61,62,63,64,65]). Lee et al. described the use of heat killed S. aureus strains producing the main capsular antigens found in mastitis strains [66]. Capsular polysaccharides alone have also been tested as potential vaccine antigens [67], as have been toxoids such as α-toxin and hemolysin β, which are regularly produced by bovine S. aureus strains [66,68]. Despite decreasing mastitis occurrence and accelerating remission, none of them proved to be fully able to prevent new infections [69,70,71,72]. Vaccines based on live attenuated S. aureus strains have been tested with promising results in terms of antibody generation [73,74,75]. The T cell response, however, has not been studied in the described vaccination trials.

Lawrence and coworkers immunized calves with heat-killed S. aureus and tested 43 recombinant S. aureus proteins for eliciting a recall T cell response. The screen identified 13 T cell antigens that were able to induce strong proliferation in CD4+ T cells and may therefore represent novel vaccine targets [76]. In order to activate CD8+ T cells as well, Pujol et al. used a soluble trimeric form of bovine CD40L as an adjuvant in S. aureus vaccination in heifers. Three animals were vaccinated on one side with non-adjuvanted and on the other with adjuvanted heat killed S. aureus. The bovine CD40L enhanced the number of antigen-responsive CD4+ and CD8+ T cells in the draining lymph node as well as their reactivity [77]. Challenge infections were not performed in these studies.

2.3. Evidence from Humans

In humans, equilibrium with S. aureus is usually maintained for many years or even decades [78]. Epidemiological evidence for a role of T cells comes from observations in patients suffering from inborn or acquired T cell deficiencies. These provide indirect evidence for a protective function of T cells. Patients with genetic defects in TH17 cell development and function are highly susceptible to S. aureus infection [79,80,81,82,83,84]. S. aureus is also among the major pathogens affecting HIV patients, once the virus has strongly reduced CD4+ T cell counts and functions [85,86]. In a Canadian study, HIV infection increased the relative risk of S. aureus invasion by a factor of 17 [87], and in Denmark it was discovered that HIV patients with S. aureus blood stream infection are also more prone to develop a secondary disease episode than HIV-negative persons [88].

T cell involvement in S. aureus interaction with its human host is also implied by the strong antibody response targeting a broad repertoire of S. aureus antigens in health as well as infection [89,90,91]. The demonstration of a strain-specific component in an individual’s anti-S. aureus antibody profile makes a strong case for the notion that the antibodies are generated in an antigen-driven process rather than being produced due to polyclonal B cell activation. [92,93]. The generation of antigen-specific, high affinity class switched antibodies, however, requires the help of T cells specific for the same antigen [94,95].

Using inactivated S. aureus cells to stimulate isolated T cell subpopulations, the group of Zielinski found reactive T cells predominantly in the TH1 and TH17 subsets, but some TH2 cells could also be stimulated by the microbe [96]. Other groups also observed proliferation of human T cells when blood cells of healthy donors were stimulated with inactivated S. aureus cells [47,97]. Brown and coworkers reported that IFN-γ was the dominant cytokine released into the cell culture [47]. In another approach, Zielinski and coworkers primed human blood cells with inactivated S. aureus cells in vitro. This resulted in the expansion of TH17 cells, which upon re-stimulation acquired the ability to produce IL-10 in addition to IL-17 [98]. A TH1/TH17 profile was also most common in T cell clones responding to extracellular S. aureus antigens [97]. To study the magnitude of the human S. aureus-specific T cell pool, Kolata and coworkers challenged human peripheral blood T cells from healthy adults with a number of recombinant S. aureus proteins selected from the extracellular bacterial proteome. The observed frequencies of the reacting T cells corresponded to a memory response in most cases. Remarkably, there was a 35-fold difference between high and low responders, probably reflecting the individuals’ history of (invasive) encounters with S. aureus. The group estimated that on average more than 3% of the peripheral T cells were specific for S. aureus, underlining that maintaining an equilibrium with S. aureus places a heavy cost on the immune system [97].

In a seminal clinical study, Brown and coworkers examined patients with blood stream infection and found increased IFN-γ serum concentrations in S. aureus but not E. coli infection. The patients’ CD4+ and CD8+ T cells proliferated ex vivo in response to S. aureus in an antigen-specific manner, and the CD4+ T cells produced IFN-γ. Under the same conditions, the number of IL-17-secreting cells was low [47].

To date, the analysis of the natural human T cell response to S. aureus has been focused on inflammatory T helper cells of the TH1/TH17 type. However, type 2 cytokines may also be released by S. aureus-specific T cells [97,98,99]. Importantly, anti-inflammatory effects such as those exerted by Tregs have not been studied in humans. They merit attention, because Tregs may act as a double-edged sword in infection, limiting organ damage due to inflammation at the price of interfering with bacterial clearance thereby promoting chronification [100,101,102].

The search for the molecular targets of S. aureus-responsive human T cells is still in its infancy. The most comprehensive study has been conducted by the group of Kolata who enumerated S. aureus-specific T cells in healthy donors. Taking the human antibody response as a lead for antigen selection, they found T cells reacting to α-toxin (Hla), the phosphodiesterase GlpQ, the phospholipase Plc, the lipases Geh and Lip, the proteases SplC and D, as well as the iron scavenger IsdB. Remarkably, the T cell response to the IsdB was very low in most tested individuals [97] suggesting that vaccination with this antigen will greatly increase the specific T cell response in humans [103] as has been shown in mouse models [45]. Similar observations were reported for ClfA in healthy adults [47]. Alpha-toxin has been shown to induce a TH1 response as well as IL-17 production by T cells in humans [104,105]. In another study, staphylokinase (Sak)-specific T cells were measured in healthy human adults. The intensity of the natural T cell reaction varied strongly and generally increased with age [106]. It is not only proteins that can be recognized by T cells, for wall teichoic acids have also been demonstrated to elicit a T cell response both in mice and humans [97,107]. Extending the analysis to unconventional T cells and ILCs may uncover further S. aureus targets in the future.

Vaccination Studies in Humans

T cell responses have not yet been analyzed in human vaccine trials—with one recent exception [108]—since the vaccine approaches have targeted the antibody response aiming at maximizing opsonization capacity [109]. Unfortunately, these efforts have not met with success and did not result in significant protection [110,111,112,113,114,115]. Moreover, a large clinical trial raised a safety concern. When patients awaiting cardiothoracic surgery were vaccinated with the non-adjuvanted S. aureus protein IsdB, S. aureus infection occurred with similar frequency in vaccinated and non-vaccinated patients. Mortality, however, was around fivefold higher in the vaccinated persons [103]. Retrospectively it was shown that vaccinated patients who succumbed to S. aureus infection had undetectable serum levels of IL-2—and in most cases IL-17—at the time of vaccination, infection and during the course of the disease. [116]. Apparently, the patients’ pro-inflammatory T cells were unable to react to vaccination or infection. It is tempting to speculate that in these patients the vaccine had enhanced pre-existing mechanisms of active suppression, possibly by boosting specific Tregs.

The use of recombinant Sak for fibrinolytic therapy in myocardial infarction provides a window of opportunity for the study of S. aureus specific T cell-reactions in humans. Intravenous exposure to Sak increased the specific T cell response four weeks later. In one individual the time course of the T cell response was monitored, showing that the increase was maximal after four weeks but had not returned to baseline at 44 weeks, just as one would expect of a T cell memory response [106]. The influence of the elicited S. aureus-specific effector and memory T cells on the course of subsequent S. aureus infections was not addressed in this study. In a recent phase I clinical trial of an S. aureus vaccine composed of four antigens specific memory T cells were induced at low levels, whereas the vaccine elicited a robust antibody response. The reasons for this discrepancy are as yet unknown [108]. Nevertheless, the findings indicate that T cells respond to vaccination with S. aureus antigens. The quality of the T cell response elicited by different S. aureus antigens and its effects on subsequent infection remain to be investigated.

2.4. A Special Case: S. aureus Persisting Inside Host Cells

It is now well established that, besides its typical extracellular life-style, S. aureus is able to persist inside a number of cell types: epithelial and endothelial cells, keratinocytes, osteoclasts, as well as in professional phagocytes such as macrophages and neutrophils [19,117,118]. Intracellular S. aureus could be an endogenous reservoir for re-colonization and/or -infection, and the intracellular life-style of the micro-organism has been implied in the pathogenesis of chronic and difficult to treat S. aureus disease such as osteomyelitis [117]. It appears that the bacteria may even use granulocytes as Trojan horses facilitating metastatic infection and abscess formation, which may complicate S. aureus blood stream invasion [119]. Long-term intracellular persistence is associated with profound bacterial adaptation processes as has been shown both in cell culture and in infection models. The bacteria assume a dormant state known as small colony variant (SCV), which is reversible as soon as they conquer a more permissive niche or are taken into culture [120,121,122,123]. Host cells react to S. aureus invasion with an inflammatory response [122,124]. It is presently not known how T cells react to intracellular persisting S. aureus and whether they have a role in controlling the bacteria that have invaded this protected habitat. The cytokine IFN-γ is a potent activator of monocytes, and pre-treatment of host monocytes with IFN-γ dramatically increased their potential for killing S. aureus [125,126]. IFN-γ may be produced by a number of immune cells, namely αβ T cells, both CD4+ and CD8+, γδ T cells, NK cells as well as by ILC1. Thus all of these are of interest in this context. Moreover, the potential role of cytotoxic cells, CTLs and NK cells, should be addressed in the future.

2.5. The T Cell Response to S. aureus May Cause Harm

While defects in the adaptive immune response had been the main concern of researchers for a long time, the S. aureus research community is now weighing the possibility of immune pathology, such as hyper-inflammation or allergies elicited by S. aureus. T cells can contribute to such noxious inflammatory reactions, where damage of the host tissue appears to be out of proportion to the beneficial anti-bacterial effects. The scenario of T cell mediated hyper-inflammation can be dramatic as has been illustrated in a mouse model of viral infection. Priming of CD4+ T cells in the absence of a neutralizing antibody response caused a detrimental cytokine storm [127]. Enhancing the anti-S. aureus T cell response by vaccination may, therefore, carry the risk of promoting damaging hyper-inflammation.

Neutrophils are essential for S. aureus clearance, and T cells foster their action, e.g., by the release of IL-17, which recruits neutrophils to the site of infection, and of IFN-γ, which extends their life span. This amplifies inflammation contributing to bacterial clearance but at the same time increasing the danger of organ damage. More than a decade ago, it was reported that γδ T cells accumulating in S. aureus skin infection reduced the bacterial burden but increased the local inflammation [36]. T cells were critically involved in abscess formation induced by staphylococcal wall teichoic acids [107], and in a model of repeated skin infection, neutralization of the TH1 signature cytokine IFN-γ reduced lesion size [25]. The recent findings of McLoughlin’s group of a TH1-dominated immune response in human severe systemic S. aureus infection may point into the same direction [47]. As discussed above, the lungs are particularly sensitive to inflammation-induced organ damage and T cells contribute to this life-threatening condition [41,42]. Finally, it has been shown that, counterintuitively, neutrophil influx may expand a niche for those S. aureus strains that are able to persist inside the phagocytes [119,128].

S. aureus has also been implicated in allergies including intrinsic asthma and atopic dermatitis [129,130,131]. Allergic or type 2 inflammation is characterized by the generation of allergen-specific IgE, and TH2 cells have a crucial role in this form of immune pathology [132]. S. aureus is capable of exacerbating allergic inflammation by releasing factors that either favor the differentiation of naïve T cells into TH2 cells or activate pre-existing TH2 cells. Proteases as well as the pore-forming α-toxin disrupt the epithelial barrier facilitating allergen entry [133,134,135], while δ-toxin triggers mast cell degranulation, a central allergic effector mechanism [136]. S. aureus superantigens (see below), which potently stimulate T cells irrespective of their antigen specificity or function, can exacerbate allergic inflammation [129,137,138]. Moreover, our group has recently discovered that S. aureus releases allergens, namely proteases that are capable: (1) of eliciting a TH2 response in healthy adults; and (2) of driving allergic airway inflammation in mice [99].

2.6. How S. aureus Manipulates T Cells

S. aureus targets T cells mainly with two classes of virulence factors, pore-forming toxins and superantigens. In addition, the “superbug” has different means of modulating the quality of the anti-staphylococcal T cell response. All of this is circumstantial evidence for the importance of T cells in keeping S. aureus at bay.

T cells can be lysed by two extracellular S. aureus toxins: α-toxin is released in variable amounts by at least 95% of clinical S. aureus isolates. Upon binding to ADAM10 on the host cell surface [139], α-toxin forms heptameric pores, thereby destroying its target cells, among which are T cells [133]. Leukocidin LukDE is a two component toxin which lyses its targets after binding to the chemokine receptor CCR5, which is present on human T cells as well as on myeloid cells [140].

Due to their remarkable properties, superantigens have been the paradigm of S. aureus -T cell interaction for decades, and much is known about their action. The term superantigen was coined by Marrack and Kappler, because these toxins are extremely potent T cell activating agents [1,141]. The pan-genome of S. aureus contains 23 superantigen genes, encoding enterotoxins (SEs) and enterotoxin-like proteins (SEls) as well as toxic shock syndrome toxin-1 (TSST-1), most of which are located on pathogenicity islands or mobile genetic elements (reviewed in [2,142,143]). SEs but not SEls or TSST-1 have been shown to possess emetic properties, which is due to serotonin release in the intestine, a mechanism distinct from the superantigenicity of the toxins [144]. Around 80% of S. aureus strains, both commensal and pathogenic isolates, harbor superantigen genes, on average five to six [145,146,147,148,149], which are released by the bacteria either during exponential or post-exponential growth [150].

Superantigens are a common cause of food poisoning as well as the causative agents of toxic shock syndrome, a rare but very dramatic condition [142]. The potent T cell stimulation ability of superantigens is explained by the fact that the toxins bypass the need for antigen processing and presentation by directly bridging αβ T cell receptors with conserved structures on MHC-II molecules. A given superantigen targets all αβ T cell receptors that use particular Vβ elements, up to 20% of the whole T cell repertoire. The simultaneous activation of such large T cell numbers results in a cytokine storm manifesting itself as life-threatening toxic shock syndrome [2,142,151,152].

When studying the T cell response to S. aureus in cell culture, superantigen action may override T cell activation by conventional antigens, because these toxins can be released by the bacteria in large amounts, act at minute concentrations and activate large fractions of T cells. When addressing the antigen-specific T cell response to S. aureus, care should be taken to avoid artifacts caused by contaminating superantigens. Since these are robust molecules that cannot not reliably be inactivated by heat treatment or proteases, this is best achieved using recombinant S. aureus proteins to probe the anti-staphylococcal T cell repertoire [97].

The possible benefits conferred to S. aureus by superantigens remain a matter of discussion. During the cytokine storm of toxic shock syndrome T cells become refractory to antigen-mediated activation. They are then unable to help B cells in mounting an S. aureus-specific antibody response. In this scenario, superantigens act as a “smoke screen” hiding S. aureus from the adaptive immune system [142,153]. Moreover, during fulminant systemic inflammation, the high concentrations of the cytokine TNF in the blood interfere with phagocyte recruitment to the site of infection [142,154]. This may be due to “atopic” activation and sequestering of the cells inside the blood vessels. However, despite the fact that everyone is exposed to S. aureus in everyday life, toxic shock syndrome is a very rare condition with a yearly incidence between 3 and 7 per million inhabitants in the US between 2000 and 2006 [155]. Moreover, during harmless encounters with the bacteria such as colonization or during mild infection, superantigens themselves act as highly immunogenic conventional antigens eliciting a protective specific antibody response, which neutralizes their toxic effects [92,93,156]. This is at odds with a major superantigen function as “smoke screens”. An alternative idea is, therefore, that superantigens may promote S. aureus colonization and/or minor infections thereby facilitating bacterial persistence and transmission [143,157,158].

Besides activating or killing T cells by the two types of toxins, S. aureus can influence the quality of the T cell response, counteracting the development of an anti-bacterial TH1/TH17 profile. This may be the evolutionary advantage conferred to the microorganism by its multi-pronged pro-allergenic activity, which has been described above (Section 2.5). Peptidoglycans, components of the S. aureus cell wall, have been shown to elicit the release of the anti-inflammatory cytokine IL-10, thereby dampening the TH1/TH17 response [100,159]. Finally, phenol-soluble modulins, amphiphilic peptides that are cytolytic at high concentrations, favor the differentiation of Tregs [160], which inhibit inflammatory T cell responses.

3. Conclusions and Future Directions of Research

The development of an S. aureus vaccine is an ambitious goal as underlined by the many futile attempts in the past. Understanding the T cell response to the bacteria may be key for success, because successful vaccination relies on immune memory, a core competence of the adaptive immune system where T lymphocytes have a central role. It will, therefore, be of prime importance to address the following points: What T cell and innate lymphoid cell subsets react to S. aureus in vivo? What antigens do they recognize? How does S. aureus manipulate the strength and quality of the T cell response?

Ideally, a vaccine induces an immune memory response of appropriate quality targeted at the right antigens. But what is the appropriate quality, what are the right antigens? In order to answer these questions, we urgently need to identify correlates of protection from S. aureus disease, many of which may be expected in the T cell compartment. To identify and employ such biomarkers, simple tests need to be developed that are suitable for measuring the anti-S. aureus T cell response “at the bedside”, namely at high throughput and with small amounts of blood.

There is now broad consensus that memory T cells make an essential contribution toward S. aureus control. A number of different S. aureus antigens could serve to elicit S. aureus-reactive TH1 or TH17 cells that will recruit neutrophils to the focus of infection, so long as these antigens are conserved in S. aureus and are generated in sufficient amounts upon bacterial invasion. Similarly, if T cells were required for dealing with intracellular bacteria, S. aureus proteins that are abundant in the invasive microorganisms and that can readily be processed and presented to the T cells by the infected host cells should be selected.

On the other hand, when targeting T cells by vaccination, adverse effects, such as those caused by excessive reaction of the primed T cells to S. aureus infection, have to be avoided as well as the preferential generation of Tregs. As a prerequisite kinetics and plasticity of the T cell reaction to S. aureus have to be explored. Fine-tuning the quality of the immune response elicited by a vaccine may be achieved by careful selection of adjuvants, while the adjuvant properties of S. aureus components themselves should not be ignored, especially when designing non-adjuvanted vaccines.

Table A1

Differentiation and functions of T cell subsets.

	Inducing Cytokines	Lineage-Specific Transcription Factor	Control of …	Secreted Cytokines	Main Functions
TH1	IL-12 IFN-γ	Tbet	Intracellular vesicles	IFN-γ IL-2	Activate macrophages Help CD8+ T cells
TH2	IL-4	Gata3	Extracellular space	IL-4, IL-5, IL-9, IL-13	Recruit eosinophils Orchestrate type 2 inflammation
TH17	TGF-β IL1-β, IL-6, IL-21, IL-23	RORγT	Extracellular space	IL-17 IL-6	Enhance neutrophil response Help mucosal B cells (IgA)
TFH	IL-6, IL-21 TGF-β	Bcl6	Extracellular space	IL-21 and others	Help B cells (antibody class switch to IgG, IgA and IgE; antibody affinity maturation)
Treg	TGF-β	Foxp3		TGF-β, IL-10	Suppress T cell responses Help mucosal B cells (IgA)
CTL			Cytoplasm	IL-2, IFN-γ	Kill infected cells

CTL: Cytotoxic T lymphocyte; TFH: T follicular helper cell; TH: T helper cell; Treg: regulatory T cell.

Table A2

Parallels in differentiation and function of innate lymphoid cells (ILCs) and T cells.

Innate Lymphoid Cells				T Cells
	Inducing Cytokines	Lineage-Specific Transcription Factor	Secreted Cytokines		Inducing Cytokines	Lineage-Specific Transcription Factor	Secreted Cytokines
ILC1	IL-12, IL-15, IL-18	Tbet	IFN-γ TNF-α	TH1	IL-12 IFN-γ	Tbet	IFN-γ IL-2
ILC2	IL-25, IL-33, TSLP	Gata3, RORα	IL-4, IL-5, IL-13, amphiregulin	TH2	IL-4	Gata3	IL-4, IL-5, IL-9, IL-13
ILC3	IL-1β, IL-23	RORγt, Ahr	IL-17, IL-22, LT, GM-CSF	TH17	TGF-β IL1-β, IL-6, IL-21, IL-23	RORγt	IL-17 IL-6
NK	IL-12, IL-15, IL-18	Eomes	IFN-γ	CTL			IL-2, IFN-γ

Ahr: Arylhydrocarbon receptor; CTL: Cytotoxic T lymphocyte; ILC: innate lymphoid cell; NK: natural killer cell; TH: T helper cell.